Indian Journal of Innovative Clinical Research

Submit Manuscript

Journal Menu


Abstracting and Indexing

  • PubMed NLM
  • Google Scholar
  • Semantic Scholar
  • Scilit
  • CrossRef
  • WorldCat
  • ResearchGate
  • Academic Keys
  • DRJI
  • Microsoft Academic
  • Academia.edu
  • OpenAIRE
  • Scribd
  • Baidu Scholar

THE CLINICAL EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB MONOCLONAL ANTIBODY THERAPY IN COVID-19 PATIENTS

Article Information

G B Raman, Consultant Physician, Department of General Medicine, Medipark Hospital, Patliputra, Patna, Bihar, India

Introduction: Casirivimab–Imdevimab Monoclonal Antibody Therapy (CIMAT) is an emerging treatment for high-risk COVID-19 patients, designed to mitigate disease progression and improve clinical outcomes. However, evidence on its real-world impact remains limited. This study aimed to evaluate the clinical effectiveness of CIMAT in reducing hospital-related outcomes, including length of hospitalization, mechanical ventilation, readmissions, and mortality in high-risk COVID-19 patients.

Methods: A single-center, retrospective comparative study was conducted in a secondary care hospital in North India over 12 months (April 2021–March 2022). Data for 130 symptomatic adult COVID-19 patients were extracted from Electronic Health Records (EHR). The cohort included 65 patients who received CIMAT and 65 control patients who declined the therapy but were otherwise eligible. Baseline characteristics, primary outcome (length of hospitalization), and secondary outcomes (mechanical ventilation, readmissions, and mortality) were analyzed using appropriate statistical methods.

Results: Patients in the CIMAT group had a significantly shorter mean hospital stay compared to the control group (4.3 ± 1.2 days vs. 7.8 ± 2.1 days, p = 0.001). The need for mechanical ventilation was lower in the CIMAT group (3.1% vs. 9.2%, p = 0.03), as were readmission rates (6.2% vs. 12.3%, p = 0.02) and mortality (1.5% vs. 7.7%, p = 0.01). These results underscore CIMAT's potential in reducing disease severity and improving survival rates.

Conclusion: CIMAT significantly improves clinical outcomes in high-risk COVID-19 patients, reducing hospitalization, ventilatory support, readmissions, and mortality. These findings suggest CIMAT as an effective therapeutic option for managing severe COVID-19 risk.